Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

BeyondMD vs Ilant Health

BeyondMD
Graded #176

Higher grade

vs+10
Ilant Health
Graded #407

Lower grade

The verdict

BeyondMD takes it — 66.8/100 to 56.8/100.

BeyondMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth clinic offering competitively priced compounded semaglutide and tirzepatide.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBeyondMD +31
76
45
Dose & formulationBeyondMD +24
64
40
Clinical oversightIlant Health +9
74
83
Labs & monitoringIlant Health +8
53
61
FulfillmentBeyondMD +3
65
62
Contract termsEven
55
55
BeyondMD · left barIlant Health · right bar

The numbers

MetricBeyondMDIlant Health
WeighScore66.8/10056.8/100
GradeCC
Scorecard rank#176#407
Semaglutide$139/mo (starting dose, compounded)Not disclosed
Tirzepatide$209/mo (starting dose, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
BeyondMD

Graded #176 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
Ilant Health

Graded #407 · C

Strengths

  • Value-based, outcomes-driven obesity care model
  • Includes GLP-1 medications with transparent drug pricing for sponsors
  • Care team of board-certified obesity providers and behavioral specialists
  • Dietitians and peer navigators support adherence
  • Data-driven stratification targets the right interventions

Where it loses points

  • Distributed via employers and health plans, not direct cash-pay
  • Individuals generally cannot enroll without sponsor coverage
  • No public consumer pricing for GLP-1
  • Access gated behind organizational buyers
  • Not suited to consumers wanting direct-to-door GLP-1

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard